Estradiol acetate

Estradiol acetate
Systematic (IUPAC) name
(17β)-3-hydroxyestra-1,3,5(10)-trien-17-yl acetate
Clinical data
  • (Prescription only)
Oral, vaginal (ring)
Identifiers
1743-60-8
None
PubChem CID 6852404
ChemSpider 5254726
Chemical data
Formula C20H26O3
314.419 g/mol

Estradiol acetate (INN, USAN, BAN; brand names Femtrace, Femring, Menoring) is a synthetic ester, specifically the 3-O-acetyl ester, of the natural estrogen, estradiol. It is relatively recent to the market, having been first approved in a vaginal ring formulation as Menoring in the United Kingdom in 2001,[1] followed by another vaginal ring formulation as Femring in the United States in 2003,[2] and finally as an oral preparation as Femtrace in the United States in 2004.[2] It is used as a form of hormone replacement therapy to treat and prevent symptoms of menopause such as osteoporosis in postmenopausal women.[1][3][4][5]

See also

References

  1. 1.0 1.1 Speroff L (October 2003). "Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms". Obstetrics and Gynecology 102 (4): 823–34. doi:10.1016/s0029-7844(03)00764-6. PMID 14551014.
  2. 2.0 2.1 Sivanandy MS, Masimasi N, Thacker HL (May 2007). "Newer hormonal therapies: lower doses; oral, transdermal, and vaginal formulations". Cleveland Clinic Journal of Medicine 74 (5): 369–75. doi:10.3949/ccjm.74.5.369. PMID 17506242.
  3. Al-Azzawi F, Lees B, Thompson J, Stevenson JC (2005). "Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate". Menopause (New York, N.Y.) 12 (3): 331–9. doi:10.1097/01.gme.0000163870.03388.4d. PMID 15879923.
  4. Utian WH, Speroff L, Ellman H, Dart C (2005). "Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms". Menopause (New York, N.Y.) 12 (6): 708–15. doi:10.1097/01.gme.0000184220.63459.a8. PMID 16278614.
  5. Speroff L, Haney AF, Gilbert RD, Ellman H (2006). "Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms". Menopause (New York, N.Y.) 13 (3): 442–50. doi:10.1097/01.gme.0000182802.06762.b2. PMID 16735941.